Stoke Therapeutics replaces director as pivotal clinical push enters next phase

Stoke is a late-stage biotech advancing zorevunersen through the Phase 3 EMPEROR study in Dravet syndrome while preparing a rolling U.S. NDA submission targeted to begin in the first quarter of 2027; it is also building a second program in ADOA.

The filing changes governance, not execution. Edward Kaye is leaving the board and its Research and Development Committee, but the filing explicitly says his resignation was not due to disagreement with Stoke. 〔0〕 The replacement, Alexander “Bo” Cumbo, is classified as independent and fills the same Class III seat through the 2028 annual meeting. 〔1〕

This is a continuity signal rather than a new strategic vote. Nothing in the 8-K changes zorevunersen’s pivotal trial, the planned regulatory path, the pipeline, or management’s operating authority. The only tangible cost disclosed is standard director compensation: a $45,000 annual cash retainer and an option for 39,674 shares with an approximately $724,000 target grant-date value. 〔2〕

Bottom line: This is a routine board transition at a company whose important story remains clinical and regulatory progress. It does not materially advance or set back Stoke’s pivotal-stage business plan.